Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2004-11-13
2011-10-04
Bristol, Lynn (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C530S387100, C435S252330, C435S488000, C435S069100, C536S023530
Reexamination Certificate
active
08029789
ABSTRACT:
Disclosed are a recombinant expression vector comprising a nucleotide sequence encoding anE. coli-derived signal sequence and a nucleotide sequence encoding an immunoglobulin constant region, and a transformant transformed with the expression vector. Also, disclosed is a method of mass-producing an immunoglobulin constant region by culturing the transformant and expressing the immunoglobulin constant region in a water-soluble form.
REFERENCES:
patent: 5045312 (1991-09-01), Aston et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5349053 (1994-09-01), Landolfi
patent: 5585097 (1996-12-01), Bolt et al.
patent: 5605690 (1997-02-01), Jacobs et al.
patent: 5672688 (1997-09-01), Kobayashi et al.
patent: 5712121 (1998-01-01), Devos et al.
patent: 5723125 (1998-03-01), Chang et al.
patent: 5908626 (1999-06-01), Chang et al.
patent: 6030613 (2000-02-01), Blumberg et al.
patent: 6277375 (2001-08-01), Ward
patent: 6410008 (2002-06-01), Strom et al.
patent: 6444792 (2002-09-01), Gray et al.
patent: 6451313 (2002-09-01), Maddon et al.
patent: 6605697 (2003-08-01), Kwon et al.
patent: 6660843 (2003-12-01), Feige et al.
patent: 6797493 (2004-09-01), Sun et al.
patent: 2001/0053539 (2001-12-01), Lauffer et al.
patent: 2002/0037558 (2002-03-01), Lo et al.
patent: 2002/0081664 (2002-06-01), Lo et al.
patent: 2003/0073164 (2003-04-01), Simmons et al.
patent: 2003/0082679 (2003-05-01), Sun et al.
patent: 2003/0082749 (2003-05-01), Sun et al.
patent: 2003/0104535 (2003-06-01), Capon et al.
patent: 2004/0044188 (2004-03-01), Feige et al.
patent: 2004/0053370 (2004-03-01), Glaesner et al.
patent: 2004/0053845 (2004-03-01), Feige et al.
patent: 2005/0048572 (2005-03-01), Reilly et al.
patent: 0 464 533 (1992-01-01), None
patent: 0580171 (1994-01-01), None
patent: 62-201582 (1987-09-01), None
patent: 2003-521925 (2003-07-01), None
patent: 2004-537262 (2004-12-01), None
patent: 2005-501052 (2005-01-01), None
patent: 10-0249572 (1999-12-01), None
patent: 10-0316347 (2001-11-01), None
patent: 2003-0009464 (2003-01-01), None
patent: 97/24137 (1997-07-01), None
patent: 99/02709 (1999-01-01), None
patent: 200015661 (2000-03-01), None
patent: 00/23472 (2000-04-01), None
patent: 00/40615 (2000-07-01), None
patent: 00/69913 (2000-11-01), None
patent: 01/02440 (2001-01-01), None
patent: 01/03737 (2001-01-01), None
patent: WO 01/03737 (2001-01-01), None
patent: 01/81415 (2001-11-01), None
patent: 01/83527 (2001-11-01), None
patent: 02/057435 (2002-07-01), None
patent: 03002144 (2003-01-01), None
patent: WO 03/074679 (2003-06-01), None
patent: 03/077834 (2003-09-01), None
Adib-Conquy et al., Protein Engineering 8:859-863 (1995) (Abstract).
Data sheet from Fermantas Life Sciences for “Bacterial alkaline phosphatase” derived fromE. coli(pp. 1-3).
Lund et al. (The Journal of Immunology 1996, 157:4963-4969).
Adib-Conquy et al. (Protein Engineering 8:859-863 (1995).
Simmons and Yansura, Nature Biotechnol. 14:629-634, 1996.
Simmons et al., J. Immunol. Methods (2002) 263:133-147.
Sequence search alignment with the peptide sequence of SEQ ID No.29.
Wan et al. (Mol. Endocrinol. 17:2240-30 (2003)).
Bowie et al., (Science 247:1306 (1990).
Simmons et al. (Nat. Biotech. 14:629-634 (1996)).
Sequence search alignment for SEQ ID No. 29 (p. 1; Nov. 30, 2009).
Sequence search alignment for SEQ ID No. 36 (p. 1; Dec. 1, 2009).
Sequence search alignment for SEQ ID No. 37 (pp. 1-2; Dec. 1, 2009).
Sequence search alignment for SEQ ID No. 38 (pp. 1-2; Dec. 1, 2009).
Sequence search alignment for SEQ ID No. 39 (pp. 1-2; Dec. 1, 2009).
Sequence search alignment for SEQ ID No. 40 (pp. 1-2; Dec. 1, 2009).
Sequence search alignment for SEQ ID No. 41 (pp. 1-2; Dec. 1, 2009).
Sequence search alignment for SEQ IDNo. 42 (pp. 1-2; Dec. 1, 2009).
Sequence search alignment for SEQ ID No. 43 (pp. 1-2; Dec. 1, 2009).
Sequence search alignment for SEQ ID No. 44 (pp. 1-2; Dec. 1, 2009).
Sequence search alignment for SEQ ID No. 45 (pp. 1-2; Dec. 1, 2009).
Sequence search alignment for SEQ ID No. 46 (pp. 1-2; Dec. 1, 2009).
Bentz et al., “Improved local delivery of TGF-β2 by binding to injectable fibrillar collagen via difunctional polyethylene glycol,”J. Biomed. Mater. Res. 39(4):539-548 (Mar. 15, 1998).
van der Poll et al., “Effects of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans,”Blood 89(10):3727-3734 (May 1997).
Matsuda et al., “Proton NMR studies of the structure of the FC fragment of Human Immunoglobulin G1 Comparisons of Native and Recombinant Proteins,”Molecular Immunology 27(6):571-580 (1990).
Kitai et al, “Extracellular production of human immunoglobulin G Fc region (hlgG-Fc) byEscherichia coli,” Appl. Microbiol. Biotechnol 28(1):52-56 (Mar. 1988).
Andrews, B., et al., “A tightly regulated high level expression vector that utilizes a thermosensitivelacrepressor: production of the human T cell receptor Vβ5.3 inEscherichia coil,” Gene, 182:1-2, Dec. 5, 1996, pp. 101-109.
Japanese Office Action issued in corresponding JP Application No. 2006-539397, dated Sep. 21, 2010.
Stevenson et al., “Conjugation of Human Fcyin Closed-Hinge or Open-Hinge Configuration to Fab'yand Analogous Ligands,” The American Association of Immunologists, 1997, pp. 2242-2250.
Chapman et al., “PEGylated Antibodies and Antibody Fragments for Improved Therapy: A Review,” Advanced Drug Delivery Reviews 54, 2002, pp. 531-545.
European Search Report issued in corresponding EP Application No. 10009129.7, dated Oct. 14, 2010.
Choi Ki-Doo
Jung Sung Youb
Kim Jin Sun
Kwon Se Chang
Lee Gwan Sun
Bristol Lynn
Hanmi Holdings Co., Ltd.
Sughrue & Mion, PLLC
LandOfFree
Method for the mass production of immunoglobulin constant... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the mass production of immunoglobulin constant..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the mass production of immunoglobulin constant... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4263363